Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 479

1.

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D; GMALL Study Group.

Cancer. 2007 May 15;109(10):2068-76.

2.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG.

Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.

3.

Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.

Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD.

Leuk Res. 2005 Dec;29(12):1381-6. Epub 2005 May 31.

PMID:
15927253
4.

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.

Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group.

J Clin Oncol. 2006 Jan 20;24(3):460-6. Epub 2005 Dec 12.

5.

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2007 Feb 15;109(4):1408-13. Epub 2006 Oct 24.

6.

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A.

J Clin Oncol. 2010 Aug 1;28(22):3644-52. doi: 10.1200/JCO.2010.28.1287. Epub 2010 Jul 6.

7.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG.

Blood. 2007 Jul 15;110(2):727-34. Epub 2007 Apr 3.

8.

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F.

Blood. 2007 May 1;109(9):3676-8. Epub 2007 Jan 9.

9.

[Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].

Wang J, Huang X, Jiang B, Qin Y, Bao L, Jiang H, Chen H, Jia J, Yang S, Jiang Q.

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):120-5. doi: 10.3760/cma.j.issn.0253-2727.2014.02.013. Chinese.

PMID:
24606652
10.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H.

Blood. 2004 Jun 15;103(12):4396-407. Epub 2003 Oct 9.

12.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2005 Jul 15;106(2):458-63. Epub 2005 Apr 7.

13.

[Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].

Liu Z, Liu XL, Du QF, Xu N, Zhong M, Song LL, Yi ZS, Liu QF, Meng FY, Zhou SY.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Mar;29(3):512-5. Chinese.

14.

[Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].

Zhang YF, Chen ZM, Lou JY, Ni WM, Wang YG, Meng HT, Tong HY, Qian WB, Jin J.

Zhonghua Xue Ye Xue Za Zhi. 2011 Dec;32(12):814-8. Chinese.

PMID:
22339953
15.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG.

Blood. 2002 Sep 15;100(6):1965-71.

16.

[Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].

Cheng Z, Zhao L, Chen G, Wu D, Qiu H, Tang X, Fu C, Jin Z, Chen F, Xue S, Sun A.

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):114-9. doi: 10.3760/cma.j.issn.0253-2727.2014.02.012. Chinese.

PMID:
24606651
17.

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK, Gehrke B, Gschaidmeier H, Hoelzer D, Ottmann OG.

Blood. 2003 Jan 1;101(1):85-90. Epub 2002 Aug 22.

18.

[Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].

Bao L, Jiang B, Huang XJ, Wang DB, Qiu JY, Lu XJ, Chen H, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):31-4. Chinese.

PMID:
15946506
19.

Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.

IMAHASHI N, TOKUNAGA M, NISHIWAKI S, YANAGISAWA M, OZAWA Y, MIYAMURA K.

Rinsho Ketsueki. 2009 Nov;50(11):1612-5.

PMID:
20009435
20.

[Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].

Hirayama Y, Sakamaki S, Takayanagi N, Tsuji Y, Sagawa T, Chiba H, Maeda M, Matsunaga T, Kato J, Niitsu Y.

Rinsho Ketsueki. 2003 May;44(5):334-8. Japanese.

PMID:
12822409
Items per page

Supplemental Content

Write to the Help Desk